These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19899765)

  • 21. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
    Kalk P; Sharkovska Y; Kashina E; von Websky K; Relle K; Pfab T; Alter M; Guillaume P; Provost D; Hoffmann K; Fischer Y; Hocher B
    Hypertension; 2011 Apr; 57(4):755-63. PubMed ID: 21339476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
    Inguimbert N; Coric P; Poras H; Meudal H; Teffot F; Fournié-Zaluski MC; Roques BP
    J Med Chem; 2002 Mar; 45(7):1477-86. PubMed ID: 11906289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
    Lin CL; Winardi W; Jeng AY; Kwan AL
    Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
    Mores A; Matziari M; Beau F; Cuniasse P; Yiotakis A; Dive V
    J Med Chem; 2008 Apr; 51(7):2216-26. PubMed ID: 18324760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
    Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
    De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
    Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metallopeptide-promoted inactivation of angiotensin-converting enzyme and endothelin-converting enzyme 1: Toward dual-action therapeutics.
    Gokhale NH; Cowan JA
    J Biol Inorg Chem; 2006 Oct; 11(7):937-47. PubMed ID: 16874470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.
    Daull P; Lepage R; Benrezzak O; Cayer J; Beaudoin M; Belleville K; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    Drug Chem Toxicol; 2006; 29(2):183-202. PubMed ID: 16707327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure based drug design of angiotensin-I converting enzyme inhibitors.
    Anthony CS; Masuyer G; Sturrock ED; Acharya KR
    Curr Med Chem; 2012; 19(6):845-55. PubMed ID: 22214449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.
    Masuyer G; Akif M; Czarny B; Beau F; Schwager SL; Sturrock ED; Isaac RE; Dive V; Acharya KR
    FEBS J; 2014 Feb; 281(3):943-56. PubMed ID: 24289879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme.
    Nelissen J; Lemkens P; Sann H; Bindl M; Bassissi F; Jasserand D; De Mey JG; Janssen BJ
    Life Sci; 2012 Oct; 91(13-14):587-92. PubMed ID: 22365954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
    Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
    Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
    Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin-converting enzyme inhibitors: current status and perspectives.
    Löffler BM
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
    J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.